<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
    <channel>
        <title>Value Research Online</title>
        <atom:link href="/stories/stock/43989/ranbaxy-laboratories-ltd-amalgamation/rss/" rel="self" type="application/rss+xml" />
        <link>https://www.valueresearchonline.com/</link>
        <description>RSS Feeds | Value Research</description>
        <language>en</language>
        <copyright>Copyright 2026 Value Research India Private Limited.</copyright>
        <image>
            <title>Value Research</title>
            <url>https://www.valueresearchonline.com/assets/images/valueresearchonline-desktop.png</url>
            <link>https://www.valueresearchonline.com/</link>
        </image>

        <item>
			<title>Sun in the shade</title>
			<link>https://www.valueresearchonline.com/stories/30034/sun-in-the-shade/</link>
			<pubDate>Wed, 20 Jan 2016 12:46:00 +0530</pubDate>
			<category>Stockwire</category>
			<description>Sun Pharma has fallen some 40 per cent from its 52-week highs. What ails the country&#039;s largest pharmaceutical company and what&#039;s ahead></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/30034/sun-in-the-shade/</guid>
		</item>
		<item>
			<title>Sunny days ahead</title>
			<link>https://www.valueresearchonline.com/stories/29602/sunny-days-ahead/</link>
			<pubDate>Fri, 11 Dec 2015 11:42:00 +0530</pubDate>
			<category>Stock Analyst Choice</category>
			<description>The fall in profitability after the Ranbaxy acquisition may have weighed  heavily upon investors but it&#039;s just a matter of time that the company turns around its acquisitions></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/29602/sunny-days-ahead/</guid>
		</item>
		<item>
			<title>Companies operating with wide margins</title>
			<link>https://www.valueresearchonline.com/stories/28975/companies-operating-with-wide-margins/</link>
			<pubDate>Thu, 08 Oct 2015 12:19:00 +0530</pubDate>
			<category>Stockwire</category>
			<description>&lt;img src=&quot;https://www.valueresearchonline.com/content-assets/images/28975_28975__w320__h240__.jpg&quot; alt=&quot;Companies operating with wide margins&quot; border=&quot;0&quot; width=&quot;320&quot; height=&quot;240&quot; style=&quot;float: left; margin-right: 5px;&quot;&gt;Companies that operate with such a high share of industry profits that their nearest competitors end up playing nothing more than second fiddle to them</description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/28975/companies-operating-with-wide-margins/</guid>
		</item>
		<item>
			<title>The Sunshine Stock</title>
			<link>https://www.valueresearchonline.com/stories/27819/the-sunshine-stock/</link>
			<pubDate>Tue, 05 May 2015 12:41:00 +0530</pubDate>
			<category>Stock Analyst Choice</category>
			<description>Sun Pharmaceutical Industries is the most profitable large pharma company, having consistently improved margins over the last decade></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/27819/the-sunshine-stock/</guid>
		</item>
		<item>
			<title>Ballooning Legal Expenses</title>
			<link>https://www.valueresearchonline.com/stories/26954/ballooning-legal-expenses/</link>
			<pubDate>Thu, 15 Jan 2015 13:56:00 +0530</pubDate>
			<category>Marketwire</category>
			<description>&lt;img src=&quot;https://www.valueresearchonline.com/content-assets/images/26954_26954__w320__h240__.jpg&quot; alt=&quot;Ballooning Legal Expenses&quot; border=&quot;0&quot; width=&quot;320&quot; height=&quot;240&quot; style=&quot;float: left; margin-right: 5px;&quot;&gt;Legal expenses could be a drag on a company&#039;s profitability &amp; could also consume significant productive time. Here are 12 such companies</description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/26954/ballooning-legal-expenses/</guid>
		</item>
		<item>
			<title>The Sun Shines Brightly</title>
			<link>https://www.valueresearchonline.com/stories/26744/the-sun-shines-brightly/</link>
			<pubDate>Wed, 17 Dec 2014 15:02:00 +0530</pubDate>
			<category>Marketwire</category>
			<description>Sun Pharma has built an amazing track record of creating shareholder wealth in the last 20 years></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/26744/the-sun-shines-brightly/</guid>
		</item>
		<item>
			<title>Rambaxy's Price Rise Smells Fishy</title>
			<link>https://www.valueresearchonline.com/stories/25308/rambaxy-s-price-rise-smells-fishy/</link>
			<pubDate>Mon, 26 May 2014 14:54:00 +0530</pubDate>
			<category>Marketwire</category>
			<description>Regulator snoops as Ranbaxy&#039;s traded volumes and stock prices shoot up prior to its acquisition by Sun Pharma></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/25308/rambaxy-s-price-rise-smells-fishy/</guid>
		</item>
		<item>
			<title>Are insiders at play?</title>
			<link>https://www.valueresearchonline.com/stories/25021/are-insiders-at-play/</link>
			<pubDate>Mon, 07 Apr 2014 11:33:00 +0530</pubDate>
			<category>Stockwire</category>
			<description>Given the rise in traded volumes on the Ranbaxy counter, the rise in the company&#039;s share price does smell fishy></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/25021/are-insiders-at-play/</guid>
		</item>
		<item>
			<title>Lessons for investors in Ranbaxy's repeated problems</title>
			<link>https://www.valueresearchonline.com/stories/24506/lessons-for-investors-in-ranbaxy-s-repeated-problems/</link>
			<pubDate>Mon, 27 Jan 2014 09:14:00 +0530</pubDate>
			<category>First Page</category>
			<description>The repeated problems at Ranbaxy hold an important lesson for investors></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/24506/lessons-for-investors-in-ranbaxy-s-repeated-problems/</guid>
		</item>
		<item>
			<title>Ranbaxy Books Mammoth Losses</title>
			<link>https://www.valueresearchonline.com/stories/13149/ranbaxy-books-mammoth-losses/</link>
			<pubDate>Fri, 24 Apr 2009 19:45:00 +0530</pubDate>
			<category>Marketwire</category>
			<description>Ranbaxy&#039;s  first quarterly results showed a loss that would be regarded as humongous></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/13149/ranbaxy-books-mammoth-losses/</guid>
		</item>
		<item>
			<title>Déjà Vu All Over Again</title>
			<link>https://www.valueresearchonline.com/stories/11655/deja-vu-all-over-again/</link>
			<pubDate>Wed, 23 Jul 2008 11:20:00 +0530</pubDate>
			<category>Stock Analyst Choice</category>
			<description>The real estate sector&#039;s current fate is reminiscent of the dot-com bubble of yesteryears></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/11655/deja-vu-all-over-again/</guid>
		</item>
		<item>
			<title>We Appreciate Depreciating Rupee</title>
			<link>https://www.valueresearchonline.com/stories/11649/we-appreciate-depreciating-rupee/</link>
			<pubDate>Mon, 21 Jul 2008 17:16:00 +0530</pubDate>
			<category>Stock Analyst Choice</category>
			<description>The falling rupee might not be good for the economy, but for the export-oriented sectors it spells good news></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/11649/we-appreciate-depreciating-rupee/</guid>
		</item>
		<item>
			<title>The Troubleshooter</title>
			<link>https://www.valueresearchonline.com/stories/11512/the-troubleshooter/</link>
			<pubDate>Thu, 19 Jun 2008 16:04:00 +0530</pubDate>
			<category>Fundwire</category>
			<description>Long-term investors can go for ICICI Pru Technology></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/11512/the-troubleshooter/</guid>
		</item>
		<item>
			<title>Choppy Market</title>
			<link>https://www.valueresearchonline.com/stories/11484/choppy-market/</link>
			<pubDate>Sat, 14 Jun 2008 10:44:00 +0530</pubDate>
			<category>Stockwire</category>
			<description>The week was a volatile one for the markets, which started and ended on a bad note. Despite staging a mid-week recovery and good news on the IIP numbers, the bulls were not in control></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/11484/choppy-market/</guid>
		</item>
		<item>
			<title>What Got In, What Went Out</title>
			<link>https://www.valueresearchonline.com/stories/11479/what-got-in-what-went-out/</link>
			<pubDate>Fri, 13 Jun 2008 13:59:00 +0530</pubDate>
			<category>Fundwire</category>
			<description>The month of May saw the Sensex fall by 5%. Find out what the funds bought and sold amidst the turmoil></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/11479/what-got-in-what-went-out/</guid>
		</item>
		<item>
			<title>Surreal… but Real</title>
			<link>https://www.valueresearchonline.com/stories/11436/surreal-but-real/</link>
			<pubDate>Fri, 06 Jun 2008 10:47:00 +0530</pubDate>
			<category>Stock Analyst Choice</category>
			<description>Despite the recent market meltdown, a few stocks posted positive returns. Read on to find out which></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/11436/surreal-but-real/</guid>
		</item>
		<item>
			<title>In The Pink Of Health</title>
			<link>https://www.valueresearchonline.com/stories/11343/in-the-pink-of-health/</link>
			<pubDate>Tue, 20 May 2008 14:32:00 +0530</pubDate>
			<category>Fundwire</category>
			<description>Pharma funds have staged a smart recovery after posting negative returns for the past few years></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/11343/in-the-pink-of-health/</guid>
		</item>
		<item>
			<title>Company news this week</title>
			<link>https://www.valueresearchonline.com/stories/10461/company-news-this-week/</link>
			<pubDate>Sat, 22 Sep 2007 15:50:00 +0530</pubDate>
			<category>Stock Analyst Choice</category>
			<description>Here are brief snippets of the news concerning various companies that appeared in the media this week. ></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/10461/company-news-this-week/</guid>
		</item>
		<item>
			<title>Keep the Faith</title>
			<link>https://www.valueresearchonline.com/stories/7003/keep-the-faith/</link>
			<pubDate>Tue, 18 Nov 2003 14:46:00 +0530</pubDate>
			<category>Fund Focus</category>
			<description>Alliance Equity, the one time champion among equity funds is struggling hard to regain the top slot. With new manager at the helm, investors can wait to see if the new style brings in great numbers></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/7003/keep-the-faith/</guid>
		</item>
		<item>
			<title>Is Low NAV Cheap?</title>
			<link>https://www.valueresearchonline.com/stories/3794/is-low-nav-cheap/</link>
			<pubDate>Thu, 09 Jan 2003 11:19:00 +0530</pubDate>
			<category>Fund Basics</category>
			<description>A low NAV means a good buy. A high NAV is an expensive fund. Read ahead to unfurl this biggest myths of mutual fund investing.></description>
			<guid isPermaLink="true">https://www.valueresearchonline.com/stories/3794/is-low-nav-cheap/</guid>
		</item>
    </channel>
</rss>
